INS and type 2 diabetes mellitus: PTP1B inhibitors can serve as insulin mimickers, as well as insulin and leptin sensitizing agents [40], therefore making them an attractive option to combat T2D and obesity simultaneously, which represents an advantage over existing therapies to date.